A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
New Orleans, Louisiana 70121, United States
Greenville, South Carolina 29605, United States
Haine-st-paul, 07100, Belgium
Hefei, 230001, China
Shanghai, 200092, China
Saint-Herblain, 44800, France
Homburg / SAAR, 66421, Germany
Milan, 20132, Italy
Itabashi-ku, 173-8606, Japan
Mitaka-shi, 181-8611, Japan
Shimotsuke-shi, 329-0498, Japan
Shinjuku-ku, 160-8582, Japan
Suita-shi, 565-0871, Japan
Yufu-shi, 879-5593, Japan